Jindal Life Science Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.95 Cr
- Revenue Growth %
- Profit Growth -30507.30%
- Net Worth 6210.30%
- Total Assets 8036.63%
About Jindal Life Science
Jindal Life Science Private Limited (JLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 August 2021 (Three years and five months 6 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹5.95 Cr.
Lokesh Jindal, Vinit Singh, Surabhi Jindal, and Two other members serve as directors at the Company.
Company Details
-
Location
Jaipur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73200RJ2021PTC076674
-
Company No.
076674
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Aug 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Jindal Life Science?
Board Members (5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Lokesh Jindal | Director | 27-Aug-2021 | Current |
Vinit Singh | Director | 06-Feb-2023 | Current |
Surabhi Jindal | Director | 27-Aug-2021 | Current |
Sandeep | Director | 06-Jan-2023 | Current |
Anu Agrawal | Director | 14-Feb-2023 | Current |
Financial Performance of Jindal Life Science.
Jindal Life Science Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 30507.3% decrease in profit. The company's net worth Soared by an impressive increase of 6210.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Jindal Life Science?
In 2023, Jindal Life Science had a public holding of 63.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.95 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 5.95 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
10 Jun 2024 | Others | ₹1.00 Cr | Open |
01 Mar 2023 | Others | ₹4.95 Cr | Open |
How Many Employees Work at Jindal Life Science?
Jindal Life Science has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jindal Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jindal Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.